Sugammadex

Drug Profile

Sugammadex

Alternative Names: Bridion; MK-8616; ORG-25969; SCH-900616; Sugammadex sodium injection

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Organon
  • Developer Merck & Co
  • Class Gamma-Cyclodextrins; Muscle relaxants
  • Mechanism of Action Binding agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuromuscular blockade

Most Recent Events

  • 15 Dec 2015 Registered for Neuromuscular blockade in USA (IV)
  • 06 Nov 2015 The Anaesthetic and Analgesic Drug Products Advisory Committee of the US FDA recommends approval of sugammadex for Neuromuscular blockade in USA
  • 28 Jul 2015 The US FDA accepts resubmitted NDA for Sugammadex injection for Neuromuscular blockade for review and sets PDUFA date of 19/12/2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top